Desk›Healthcare› Natco Pharma Ltd
Natco Pharma Ltd
BSE 524816 · NSE NATCOPHARM · ISIN INE987B01026 · Group A · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹858.20
-0.61%
BSE close, 28 August 2026
₹15,371.21 cr
17.9 cr shares · Small cap
₹7,690.31 cr
as published
17.2× · 2.25×
EPS ₹49.80 · BV ₹381.42
3,594.60 / 1,281.50
₹ cr, as filed
32
12 selected · 38%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -30.0% |
|---|---|
| Against 52-week low | +8.7% |
| Day change | -0.61% |
| Size band | Small cap |
| Index membership | NIFTY 500 |
Valuation as published by BSE
| Earnings per share | ₹49.80 |
|---|---|
| Price / earnings | 17.23× |
| Price / book | 2.25× |
| Book value — derived, price ÷ P/B | ₹381.42 |
| Return on equity | 13.04% |
| Operating margin | 25.86% |
| Net margin | 12.50% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 13.06%
- ROE as published
- 13.04%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 596.60 | 74.60 | 4.17 | 25.86% | 12.50% |
| Mar-26 · Q | 608.80 | 209.60 | 11.70 | 27.15% | 34.43% |
| FY25-26 | 3,594.60 | 1,281.50 | 71.55 | 44.12% | 35.65% |
Quarter on quarter
- Revenue, quarter on quarter
- -2.0%
- Net profit, quarter on quarter
- -64.4%
- Operating margin, quarter on quarter
- -129 bps
Disclosure profile 32 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Board Outcome | 3 |
| Press Release | 3 |
| Fundraising | 2 |
| Investor Presentation | 2 |
| Concall Transcript | 1 |
| Dividend | 1 |
| Selected sub-total | 12 |
| Procedural | |
| Analyst / Investor Meet | 5 |
| Board Meeting | 4 |
| AGM / EGM | 3 |
| Annual Report | 1 |
| BRSR | 1 |
| General | 1 |
| Newspaper Publication | 1 |
| Outcome | 1 |
| Record Date | 1 |
| SAST | 1 |
| Trading Window | 1 |
| Procedural sub-total | 20 |
| Total | 32 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group A, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
32 filings · 12 selected · busiest 2026-08-14 and 2026-09-04
Filing rhythm · the twelve most recent
2026-09-092026-10-07
SelectedProcedural
Filings
32 in the window · 9 earlier on record
-
7 October 2026 ·
-
30 September 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer's Report
Evoting Results along with Scrutinizer Report for the 43rd Annual General Meeting held on 30/09/2026
AGM/EGM / AGM View filing →
-
30 September 2026 ·
Closure of Trading Window
Closure of Trading Window
Insider Trading / SAST / Closure of Trading Window View filing →
-
30 September 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of the 43rd Annual General Meting
AGM/EGM / AGM View filing →
-
28 September 2026 ·
Board Meeting Outcome for Outcome Of Fund Raising Committee Meeting Approving The Letter Of Offer For Rights Issue
Outcome of Fund Raising Committee Meeting approving the Letter of Offer for Rights Issue
Others / Outcome without intimation View filing →
-
28 September 2026 ·
Press Release / Media Release
Press Release and disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Company Update / Press Release / Media Release View filing →
-
25 September 2026 ·
Intimation Of Record Date For Rights Issue
Intimation of Record Date for Rights Issue
Corp. Action / Record Date View filing →
-
25 September 2026 ·
-
25 September 2026 ·
Board Meeting Outcome for Out Come Of Board Meeting
Natco Pharma Limited has informed the Exchange that Board of Directors at its meeting held on September 25, 2026, has decided to issue equity shares on rights basis in the ratio of 2 : ....
Board Meeting / Outcome of Board Meeting View filing →
-
22 September 2026 ·
Board Meeting Intimation for Rights Issue Of Equity Shares
Natco Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/09/2026 ,inter alia, to consider and approve to consider, discuss and decide ....
Board Meeting / Board Meeting View filing →
-
21 September 2026 ·
Receipt Of In-Principal Approval For Rights Issue Of Equity Shares
Receipt of In-principal approval for Rights Issue of Equity Shares
Company Update / General View filing →
-
9 September 2026 ·
-
9 September 2026 ·
Board Meeting Outcome for Outcome Of Board Meeting
Outcome of Board Meeting
Board Meeting / Outcome of Board Meeting View filing →
-
4 September 2026 ·
Notice Of 43Rd Annual General Meeting
Notice of 43rd Annual General Meeting of the Company scheduled to be held on Wednesday, the September 30, 2026 at 11:00 AM (IST)
AGM/EGM / AGM View filing →
-
4 September 2026 ·
Business Responsibility and Sustainability Reporting (BRSR)
Business Responsibility and Sustainability Report
Others / Business Responsibility and Sustainability Reporting (BRSR) View filing →
-
4 September 2026 ·
Reg. 34 (1) Annual Report.
Annual Report for the FY 2025-26
Others / Reg. 34 (1) Annual Report View filing →
-
4 September 2026 ·
Board Meeting Intimation for Fund Raising
Natco Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/09/2026 ,inter alia, to consider and approve Fund Raising
Board Meeting / Board Meeting View filing →
-
2 September 2026 ·
Analyst / Investor Meet - Intimation
Investor Meet
Company Update / Analyst / Investor Meet View filing →
-
26 August 2026 ·
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Durga Devi Nannapaneni
Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 View filing →
-
25 August 2026 ·
Press Release / Media Release
Press Release & Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 regarding the investment in eGenesis, Inc.
Company Update / Press Release / Media Release View filing →
-
24 August 2026 ·
Analyst / Investor Meet - Intimation
Intimation of Investor Meet
Company Update / Analyst / Investor Meet View filing →
-
21 August 2026 ·
Press Release / Media Release
Conclusion of US FDS Inspection at our Visakhapatnam, Andhra Pradesh, Finished Dosage (FDF) Unit
Company Update / Press Release / Media Release View filing →
-
19 August 2026 ·
Analyst / Investor Meet - Intimation
Investor Meet
Company Update / Analyst / Investor Meet View filing →
-
19 August 2026 ·
-
18 August 2026 ·
Earnings Call Transcript
Q1FY2026-27 Transcript for the Earnings call held on 14th August, 2026
Company Update / Earnings Call Transcript View filing →
-
14 August 2026 ·
Analyst / Investor Meet - Outcome
Weblink of Audio Transcript for the earnings call held on 14th August, 2026 for Q1FY2026-27
Company Update / Analyst / Investor Meet View filing →
-
14 August 2026 ·
Investor Presentation
Investor Presentation for the Q1FY27
Company Update / Investor Presentation View filing →
-
14 August 2026 ·
Corporate Action-Board approves Dividend
Board of Directors at their Meeting held on today i.e. 14th August, 2026 had declared Interim Dividend of Rs.1.50 (75%) for face value of Rs.2/- each
Corp. Action / Dividend View filing →
-
14 August 2026 ·
Board Meeting Outcome for Outcome Of Board Meeting
Outcome of Board Meeting
Board Meeting / Outcome of Board Meeting View filing →
-
11 August 2026 ·
Analyst / Investor Meet - Intimation
The Company will host an Earnings Call with Investors / Analysts on Friday, the 14th August, 2026 at 17:30 PM IST to discuss the Un-audited Financial Results of the Company for the quarter ....
Company Update / Analyst / Investor Meet View filing →
-
11 August 2026 ·
Update on board meeting
Natco Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Further to our earlier intimation ....
Board Meeting / Board Meeting View filing →
-
6 August 2026 ·
Board Meeting Intimation for Considering Un-Audited Financial Results For The Quarter Ended 30Th June, 2026 And Declare Interim Dividend, If Any
Natco Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Un-audited Financial Results for ....
Board Meeting / Board Meeting View filing →
RSS feed for Natco Pharma Ltd · the 50 most recent filings